Concepts (85)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clinical Clerkship | 2 | 2017 | 91 | 0.520 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 78 | 0.490 |
Why?
|
| Internal Medicine | 1 | 2017 | 160 | 0.480 |
Why?
|
| Career Choice | 1 | 2017 | 132 | 0.470 |
Why?
|
| Curriculum | 2 | 2017 | 600 | 0.410 |
Why?
|
| Students, Medical | 3 | 2017 | 262 | 0.290 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2017 | 158 | 0.230 |
Why?
|
| Fluorouracil | 1 | 2024 | 66 | 0.220 |
Why?
|
| RNA, Ribosomal | 1 | 2024 | 56 | 0.220 |
Why?
|
| DNA Damage | 1 | 2024 | 287 | 0.190 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 276 | 0.180 |
Why?
|
| Enterococcus faecium | 1 | 2020 | 7 | 0.170 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2020 | 1 | 0.170 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2020 | 11 | 0.160 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2020 | 12 | 0.160 |
Why?
|
| Vancomycin | 1 | 2020 | 39 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 30 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2014 | 762 | 0.140 |
Why?
|
| Learning | 2 | 2016 | 182 | 0.140 |
Why?
|
| Medication Adherence | 1 | 2019 | 204 | 0.140 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2019 | 228 | 0.130 |
Why?
|
| Medical Errors | 1 | 2018 | 196 | 0.130 |
Why?
|
| Social Environment | 1 | 2016 | 93 | 0.120 |
Why?
|
| Forecasting | 1 | 2017 | 232 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2018 | 361 | 0.120 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2019 | 216 | 0.120 |
Why?
|
| Perception | 1 | 2016 | 174 | 0.120 |
Why?
|
| HIV Infections | 2 | 2012 | 970 | 0.110 |
Why?
|
| Adaptation, Psychological | 1 | 2016 | 267 | 0.110 |
Why?
|
| Cultural Diversity | 1 | 2014 | 53 | 0.100 |
Why?
|
| Young Adult | 4 | 2017 | 4700 | 0.100 |
Why?
|
| AIDS Serodiagnosis | 1 | 2012 | 19 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 598 | 0.090 |
Why?
|
| Narcotics | 1 | 2012 | 58 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 919 | 0.090 |
Why?
|
| Education, Medical | 1 | 2014 | 185 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2017 | 690 | 0.090 |
Why?
|
| Surveys and Questionnaires | 5 | 2019 | 2681 | 0.080 |
Why?
|
| Opiate Substitution Treatment | 1 | 2012 | 206 | 0.080 |
Why?
|
| Buprenorphine | 1 | 2012 | 192 | 0.080 |
Why?
|
| Phylogeny | 2 | 2020 | 377 | 0.070 |
Why?
|
| Male | 7 | 2020 | 29927 | 0.070 |
Why?
|
| Female | 7 | 2020 | 32912 | 0.070 |
Why?
|
| Humans | 10 | 2024 | 63512 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 712 | 0.060 |
Why?
|
| Mass Screening | 1 | 2012 | 691 | 0.060 |
Why?
|
| Vietnam | 2 | 2019 | 173 | 0.060 |
Why?
|
| Opioid-Related Disorders | 1 | 2012 | 507 | 0.060 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2024 | 17 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 2578 | 0.050 |
Why?
|
| Ribosomes | 1 | 2024 | 163 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2020 | 2574 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 1256 | 0.040 |
Why?
|
| Adult | 5 | 2019 | 16837 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 1471 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2020 | 32 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 115 | 0.040 |
Why?
|
| United States | 3 | 2020 | 7855 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 205 | 0.040 |
Why?
|
| Blood Specimen Collection | 1 | 2018 | 20 | 0.040 |
Why?
|
| Ticlopidine | 1 | 2019 | 49 | 0.040 |
Why?
|
| Blood Banks | 1 | 2018 | 9 | 0.040 |
Why?
|
| Cross Infection | 1 | 2020 | 164 | 0.040 |
Why?
|
| Income | 1 | 2019 | 169 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 498 | 0.040 |
Why?
|
| Genotype | 1 | 2020 | 663 | 0.040 |
Why?
|
| Aspirin | 1 | 2019 | 172 | 0.030 |
Why?
|
| Heart | 1 | 2019 | 283 | 0.030 |
Why?
|
| Genomics | 1 | 2020 | 371 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 937 | 0.030 |
Why?
|
| Middle Aged | 3 | 2020 | 17641 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2019 | 512 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 777 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 790 | 0.030 |
Why?
|
| Empathy | 1 | 2014 | 67 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 3301 | 0.020 |
Why?
|
| Utilization Review | 1 | 2012 | 32 | 0.020 |
Why?
|
| Stereotyping | 1 | 2011 | 19 | 0.020 |
Why?
|
| Knowledge | 1 | 2011 | 31 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2012 | 162 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1655 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 1120 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2018 | 6670 | 0.020 |
Why?
|
| Aged | 1 | 2020 | 14469 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 6248 | 0.010 |
Why?
|